36 results about "Polymeric nanoparticles" patented technology

A construction and use of an environmentally adaptive co-regulated mRNA nanodelivery system. By incorporating EACR molecules into mRNA nanoparticles, the microenvironment is remodeled to be suitable for robust and sustained mRNA expression, while tissue damage associated with the self-immunogenicity of mRNA drugs is avoided. The nanodelivery system is compatible with ionizable lipid nanoparticles, cationic liposomes, cationic nanoemulsions, and polymeric nanoparticles. The EACR molecules include: anti-inflammatory drugs, tyrosine kinases / adaptors, JAK / STAT and MAPK pathway inhibitors, nutrients and metabolites, membrane transporters / ion channels, phosphodiesterase and cellular stress inhibitors, and natural viral proteins. The therapeutic mRNAs may encode tumor, viral, or bacterial antigens, immunomodulatory factors, therapeutic antibodies, or functional proteins / enzymes, and can play a role in the fields of regenerative medicine, protein supplementation / replacement therapy, targeted gene editing, and immunotherapy.

The invention discloses a preparation method and application of a nano heat-insulating metal oxide composite coating. The preparation method comprises the following steps: preparing a nano ATO crystal of which the surface contains silicon hydroxyl; preparing polymerizable ATO (antimony tin oxide) nano particles; and uniformly mixing the polymerizable ATO nano particles, the silane modified nano silicon dioxide, the self-emulsifying polyurethane emulsion and the auxiliary agent to obtain the required coating. Nanometer ATO crystallization and surface silicon hydroxyl modification are synchronously completed in a hydrothermal environment, and the problem of uneven coating caused by traditional two-step modification is solved; after the high-temperature reaction, cold ethanol is used for realizing shock cooling to stop crystal growth, so that the problem of thermodynamic instability of the nanocrystalline is solved; the interfacial compatibility is improved by introducing a vinyl-containing siloxane monomer; by compounding the polymerizable ATO nano particles, the silane modified nano silicon dioxide, the self-emulsifying polyurethane emulsion and the auxiliaries, a stable topological structure connected by covalent bonds is constructed, and the aging resistance, the heat insulation property and the adhesive force of the coating are remarkably improved.

A polymeric nanoparticle is disclosed which comprises:(i) at least one disease-associated antigen which is capable of producing a T-cell response, wherein the disease-associated antigen is encapsulated in the nanoparticle;(ii) at least one adjuvant; and(iii) a dendritic cell targeting moiety which is attached to the outer surface of the nanoparticle.Use of the nanoparticle for treating diseases associated with abnormal cell growth or an infection is also disclosed.

The present invention deals with the development of novel nanocomposite paints for biofouling removal coatings, which result from the mixing of two components, where the first component is an epoxy resin (component A) and the second component is a suitably modified polymerization agent (hardener). These hardeners are modified with hydrophobic nanoparticles based on functional dendritic polymers with symmetric or asymmetric architecture or based on functional inorganic nanoparticles (metal or metalloid nanoparticles or a mixture thereof). Both the polymeric nanoparticles and the inorganic nanoparticles were modified with suitable lipophilic groups. These nanocomposite paints addressed by the present invention exhibit organic microfilm control properties and can be effectively applied to objects immersed in seawater as biofouling removal coatings.

In various embodiments tolerogenic nanoparticles are provided that induce immune tolerance to one or more desired antigen(s) and / or that reduce an immune response to those antigen(s). In certain embodiments the tolerogenic nanoparticle comprises a nanoparticle comprising a biocompatible polymer; an antigen disposed within or attached to said biocompatible polymer where said antigen comprises an antigen to which immune tolerance is to be induced by administration of said tolerogenic nanoparticle to a mammal; and a first targeting moiety that binds to a scavenger receptor in the liver, and / or a second targeting moiety that binds to a mannose receptor in the liver, and / or a third targeting moiety that binds to hepatocytes, wherein said first and / or second and / or third targeting moiety are attached to the surface of said nanoparticle.

Nanoparticle compositions and methods for preparation thereof are provided. The compositions include nanoparticles comprising anionic polymers, therapeutic agents, and cations. Nanoparticles predominantly fall within a diameter range of 10 nm to 80 nm. Method of preparation involves mixing anionic polymers with cations and therapeutic agents in a microfluidic device to produce nanoparticles.

Provided herein are nanoparticles comprising a triblock copolymer and a targeting moiety for targeted delivery of one or more therapeutic agents, and formulations thereof. Also provided herein are layered drug delivery vehicles. Further provided herein are methods, or uses thereof, for treating cancers, preferably pancreatic and brain cancers, by administration of the nanoparticles disclosed herein.

Bioadhesive and biodegradable polymeric nanoparticles can be administered intrathecally, for example, via the cisterna magna, into the spinal column to allow widespread distribution for the treatment of tumors such as leptomeningeal metastases. The nanoparticles rapidly spread to all cerebrospinal fluid (CSF) compartments, including the brain parenchyma and spinal column. The bioadhesive nanoparticles penetrate and are retained for long periods of time, during which time they can continue to release drugs. These nanoparticles can be loaded with different therapeutic, preventive, or diagnostic agents, most preferably DNA repair inhibitors, to enhance the killing of leptomeningeal tumors, such as leptomeningeal metastases, and disseminated tumors, such as medulloblastoma. In a preferred embodiment, patients are treated with a combination of a PARP inhibitor and temozolomide.

The present disclosure provides polymeric nanoparticles including block copolymers which possess reactive oxygen species (ROS) quenching units to reduce oxidative stress to prevent neurodegeneration and which can also be used to encapsulate an active pharmaceutical ingredient, a diagnostic marker, or a combination thereof in a pharmaceutical composition. The polymeric nanoparticles of the present disclosure are designed to release ROS quenchers, the active pharmaceutical ingredient, the diagnostic marker, or the combination thereof upon exposure to a pH below about 6.5, exposure to a reactive oxygen species, or a combination thereof. Methods of diagnosing or treating radiotherapy-induced brain injuries in a patient are also described.

The invention relates to a composition for use in the treatment or prevention of one or more unwanted immune responses in a subject, wherein the one or more unwanted immune responses are caused by the use of one or more immunogenic drugs and wherein the composition comprises negatively charged non-polymeric nanoparticles, wherein the negatively charged non-polymeric nanoparticles are selected from the group consisting of at least one of silicon particles, solid lipid particles comprising at least one immune modulating drug and liposomes comprising at least one immune modulating drug.

The present disclosure relates to compositions and methods for treating genetic disorders caused by nonsense mutations using anticodon-engineered transfer RNA (ACE-tRNA) constructs. These DNA-based ACE-tRNA constructs are designed to suppress premature termination codons (PTCs) and restore the expression of full-length, functional proteins. The disclosure further provides formulations of ACE-tRNA constructs with poly(amine-co-ester) (PACE) polymeric nanoparticles to improve stability, protect nucleic acids, and enhance delivery to airway epithelial cells. Also described are functionalized ACE-tRNA Picovectors (sLPVs) incorporating targeting elements such as nuclear localization signals (NLSs), nucleolar localization sequences (NoLSs), and DNA nuclear targeting sequences (DTSs) to improve nuclear import and localization.

Disclosed herein are polymeric nanoparticles containing peptides, which provide low burst release and sustained, delivery of the peptides, and pharmaceutical compositions thereof. The polymeric nanoparticles contain a peptide encapsulated or dispersed therein. The nanoparticles can provide sustained release of the peptide, for example, less than 20% of the peptide is released initially (at time 0 hour) following placement into a phosphate buffered saline at pH 7.4 at 37° C. and room pressure. Methods for micronizing a peptide and for preparing polymeric nanoparticles containing solid, micronized peptides are also disclosed. The preparation methods use miscible solvent and non-solvent pairs in phase inversion nanoencapsulation processes. The Gibbs energy of mixing (ΔGMix) between the solvent and non-solvent can be tailored to achieve desired particle size, encapsulation efficiency, and release profile.

Microalgae combined with antibiotic-loaded neutrophil membrane-coated polymeric nanoparticles provide a hybrid microrobot having robust locomotion in the lungs in vivo toward effective treatment of pulmonary and gastrointestinal tract infections. The algae-nanoparticle hybrid microrobots are provided in methods of treatment of disease or conditions by administration for active in vivo delivery of therapeutics to the lungs or gastrointestinal tract. The microrobot system can be applied to treat a wide range of diseases, including viral pneumonia.

The invention discloses a polypeptide modified cationic polymer nanoparticle as well as a preparation method and application thereof, and relates to the technical field of genetic engineering medicine and vaccine manufacturing, the polypeptide modified cationic polymer nanoparticle comprises a cationic polymer nanoparticle PBAE-536 and plasmid DNA which is in electrostatic binding and tight winding with the PBAE-536; the cell-penetrating peptide HIV-TAT is indirectly coupled to the surface of the PBAE-536, the auxiliary peptide HA2-TAT is mixed with the PBAE-536, and the oligopeptide is coupled with a carrier of the PBAE-536 and contains a microtubule related sequence MTAS and a nuclear localization signal NLS; the polypeptide modified cationic polymer nanoparticles have low cytotoxicity, and can enter cells through endocytosis after being incubated with T lymphocytes from peripheral blood for 30 minutes, so that rapid and efficient gene delivery is realized.

Therapeutic compositions for treating a subject, the compositions including a polymeric nanoparticle, an active agent encapsulated within the polymeric nanoparticle, and a delivery vehicle for targeted delivery of the polymeric nanoparticle and encapsulated agent to a target tissue in the subject. The therapeutic compositions can be designed for targeting the destruction of a Nuclei neutrophil extracellular trap (NET) in a venous thrombus in a subject. The active agent can be an enzyme, including deoxyribonuclease 1 (DNase 1) enzyme. Methods of treating a subject using the therapeutic compositions are provided, including methods of treating venous thrombus, deep vein thrombosis, or a related blood clotting disease and / or condition.

Described are new biodegradable nanoparticle platforms for encapsulation and sustained release of protein therapeutics through a scalable and reproducible method. Specifically nanoparticles comprising a complex comprising a protein, or peptide, and a counter ion polymer are described.

The present invention relates to a thyroid hormone delivery system comprising lipid or polymeric nanoparticles, preferably a targeting agent comprising the TRCP6 receptor. The delivery system can be used for treating diabetic cardiomyopathy or diabetic nephropathy.

The present invention relates to polymeric nanoparticles of metabolites, a method for promoting cell activity using the same, and a composition for promoting cell activity including the same. Specifically, the present invention relates to a method and composition in which polymeric nanoparticles of metabolites penetrate into cells to promote cell activity, such as intercellular or intertissue adhesion, hemostasis, promotion of wound healing, hair root regeneration activity, and antibacterial activity.

The present invention relates to nanoparticles formed by a hollow polymeric wall, capable of transporting drugs and active substances, or contrast media, across cellular membranes and releasing them at sites of interest. The nanoparticles are formed by self-assembly of poly(isobutene-alt-maleic anhydride) functionalised with an aminosaccharide.

A composite adhesive composition is described herein. The composition comprises: a plurality of polymeric nanoparticles dispersed in a (meth) acrylate-based matrix; and the (meth) acrylate-based matrix is derived from C1 to C12 (meth) acrylate monomers and (meth) acrylate macromonomers. In some embodiments, these composite adhesives exhibit good impact resistance and good dynamic shear resistance. In one embodiment, an ionic liquid is added to the composite adhesive to achieve electrical exfoliation.

There is provided a polymeric nanoparticle comprising: a hydrophobic synthetic polymer core; and a hydrophilic bioactive shell, wherein the hydrophobic synthetic polymer core and hydrophilic bioactive shell are parts of a bioactive synthetic polymer with a poly(norbornene-dicarboximide) backbone having one or more repeating units selected from the group consisting of general formula (1), (2) and (3). Also provided are a composition comprising bioactive synthetic polymeric nanoparticles, bioactive synthetic polymers, macromolecules for preparing said bioactive synthetic polymers, related methods and uses.

The present invention relates to a polymeric nanoparticle for oral administration of physiologically active substances and a preparation method therefor and, more specifically, to a carrier or polymeric hydrogel for delivery of a physiologically active substance and a preparation method therefor, wherein the carrier or polymeric hydrogel comprises: polymeric micelles including a PEG-based block copolymer prepared by a reversible addition–fragmentation chain transfer (RAFT) radical polymerization method using a polymer that has a specific functional group at the chain end thereof and a boronic acid group introduced into the backbone thereof; and a physiologically active substance that can be encapsulated in the polymeric micelles, including a type 2 diabetes drug, insulin, an anti-obesity agent, a DPP-4 inhibitor, or an anticancer agent.

The present disclosure relates to compositions and methods for treating genetic disorders caused by nonsense mutations using anticodon-engineered transfer RNA (ACE-tRNA) constructs. These DNA-based ACE-tRNA constructs are designed to suppress premature termination codons (PTCs) and restore the expression of full-length, functional proteins. The disclosure further provides formulations of ACE-tRNA constructs with poly(amine-co-ester) (PACE) polymeric nanoparticles to improve stability, protect nucleic acids, and enhance delivery to airway epithelial cells. Also described are functionalized ACE-tRNA Picovectors (sLPVs) incorporating targeting elements such as nuclear localization signals (NLSs), nucleolar localization sequences (NoLSs), and DNA nuclear targeting sequences (DTSs) to improve nuclear import and localization.

A nanoparticle composition including: a first polymer conjugated to a drug by a linker to form a first polymer compound, the first polymer compound having a net negative charge; and a second polymer conjugated to at least one positively charged group to form a second polymer compound, the second polymer compound having a net positive charge, and the first polymer compound and the second polymer compound interacting electrostatically to form a nanoparticle.

Polymeric nanoparticles, microparticles, and gels for delivering cargo, e.g., a therapeutic agent, such as a peptide, to a target, e.g., a cell, and their use for treating diseases, including angiogenesis-dependent diseases, such as age-related macular degeneration and cancer, are disclosed. Methods for formulating, stabilizing, and administering single peptides or combinations of peptides via polymeric particle and gel delivery systems also are disclosed.

The present invention relates to fatty acid-introduced polymeric nanoparticles and their uses. In the present invention, nanoparticles embedded with calcium carbonate crystals are formed using a biocompatible polymer and an adipocyte targeting ligand (fatty acid), thereby minimizing delivery to surrounding cells and tissues other than adipocytes and maximizing embedding of nanoparticles in adipocytes. The nanoparticles according to the present invention can be produced in an injectable formulation and can be used as a localized lipolysis supplement that breaks down localized fat or as a diet beauty product.

This invention, entitled "Temperature- and pH-Sensitive BPA-Targeted Chitosan–Poly(N-isopropylacrylamide)–FPBA Core-Shell Polymeric Nanoparticles Capable of Forming COF Structures in the BNCT Therapeutic Method," pertains to an anti-cancer pharmaceutical composition utilizing novel drug delivery methods. The application of the novel BNCT method is advantageous for cancers such as glioblastoma due to the challenge of crossing the blood-brain barrier. BNCT is a dual and targeted method wherein cancer cells, following the accumulation of ¹⁰B, are irradiated with thermal neutrons. Loading boron-containing compounds into nanoparticles can deliver a high concentration of boron to human glioblastoma cells. Temperature- and pH-sensitive nanoparticles of succinylated chitosan–poly(N-isopropylacrylamide) targeted with BPA are our concept for achieving endocytosis via sialic acid receptors on the surface of glial cells and for the targeted delivery of boron to these cells. By designing temperature- and pH-sensitive, BPA-targeted Chitosan–Poly(N-isopropylacrylamide)–FPBA core-shell polymeric nanoparticles with the capability of forming COF structures in order to simultaneously deliver BPA and FPBA, we aim to utilize the polymeric boron content to perform treatment via the BNCT method. Consequently, damage to healthy cells is reduced to a minimum, and even to zero.

Provided herein are nanoparticles comprising a triblock copolymer and a targeting moiety for targeted delivery of one or more therapeutic agents, and formulations thereof. Also provided herein are layered drug delivery vehicles. Further provided herein are methods, or uses thereof, for treating cancers, preferably pancreatic and brain cancers, by administration of the nanoparticles disclosed herein.

Embodiments of the present disclosure provide for compositions including polymer particles, methods of making compositions, methods of using the composition, stimuli-responsive methods of delivering agents, and the like.

Disclosed are polymeric nanoparticles and microparticles having a tunable elastic modulus and having one or more biological proteins conjugated to a surface thereof and their use in immunotherapies for treating diseases, such as cancer or infectious diseases.